The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Abstract
Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20% to 30% of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationNew Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×
“Increasing evidence suggests that anti-VEGF therapy may increase the tendency of tumor cells to co-opt existing blood vessels, resulting in an invasive nonenhancing phenotype.(52-54) Unlike the Macdonald Criteria, which do not take into account progressive nonenhancing disease, the new response assessment will conside…”
BackgroundResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Self-citationOutcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
Self-citation
Research works printed but not linked: 48
- 10.1056/NEJMra0708126 · DOI · Paper page
- 10.1215/15228517-2007-062 · DOI · Paper page
- 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 · DOI · Paper page
- 10.1097/00019052-200312000-00001 · DOI
- 10.1093/jnci/93.18.1401 · DOI
- 10.1215/S1522851705000529 · DOI · Paper page
- 10.1215/15228517-2005-005 · DOI
- 10.1200/JCO.2001.19.2.551 · DOI · Paper page
- 10.1038/ncponc1204 · DOI · Paper page
- 10.3174/ajnr.A0963 · DOI
- 10.1200/JCO.2009.22.4998 · DOI · Paper page
- 10.1212/WNL.38.5.724 · DOI
- 10.1200/JCO.1994.12.9.1886 · DOI
- 10.3171/jns.1996.84.2.0174 · doi:10.3171/jns.1996.84.2.0174
- 10.1148/radiology.217.2.r00nv36377 · DOI · Paper page
- 10.1212/01.wnl.0000242894.21705.3c · DOI
- 10.1016/j.surneu.2006.04.015 · doi:10.1016/j.surneu.2006.04.015
- 10.6004/jnccn.2008.0037 · DOI
- 10.1212/01.WNL.0000133398.11870.9A · DOI · Paper page
- 10.1016/S1470-2045(08)70125-6 · DOI · Paper page
- 10.1007/s11060-006-9241-y · DOI · Paper page
- 10.1002/cncr.23562 · DOI · Paper page
- 10.1200/JCO.2007.14.8163 · DOI · Paper page
- 10.1002/ana.410170607 · doi:10.1002/ana.410170607
- 10.1148/radiology.204.3.9280269 · doi:10.1148/radiology.204.3.9280269
- 10.1017/S0317167100046643 · DOI
- 10.3171/jns.2005.103.3.0428 · DOI
- Matheus MG, 2004, Am J Neuroradiol, 25, 1211
- 10.3171/jns.2005.102.2.0267 · DOI
- Floeth FW, 2001, Am J Neuroradiol, 22, 1517
- 10.1023/A:1014571900854 · doi:10.1023/a:1014571900854
- 10.1016/j.ncl.2007.07.010 · DOI
- 10.2967/jnumed.106.037689 · DOI · Paper page
- 10.1016/j.crad.2008.07.002 · DOI · Paper page
- 10.1016/j.crad.2006.09.012 · doi:10.1016/j.crad.2006.09.012
- 10.1016/j.ccr.2006.11.021 · DOI · Paper page
- 10.1200/JCO.2007.12.2440 · DOI · Paper page
- 10.1200/JCO.2008.19.8721 · DOI · Paper page
- 10.1200/JCO.2008.16.3055 · DOI · Paper page
- 10.1007/s11060-008-9745-8 · DOI
- 10.1158/0008-5472.CAN-09-0814 · DOI · Paper page
- 10.1212/01.wnl.0000304121.57857.38 · DOI · Paper page
- 10.1200/jco.2008.26.15_suppl.13000 · DOI
- 10.1016/S1474-4422(08)70260-6 · DOI · Paper page
- 10.1038/sj.neo.7900102 · DOI · Paper page
- 10.1016/j.ccr.2009.01.027 · DOI · Paper page
- 10.1007/978-0-387-75587-8_1 · DOI
- 10.1055/s-0028-1083696 · doi:10.1055/s-0028-1083696
Cited by
The multimodal brain tumor image segmentation benchmark (BRATS)
Menze, B. H., Jakab, A., Bauer, S., Kalpathy-Cramer, J., Farahani, K., Kirby, J., Burren, Y., Porz, N., Slotboom, J., Wiest, R., et al. (2015) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2014.2377694 · Cited by 6,781
Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation
Kamnitsas, K., Ledig, C., Newcombe, V. F. J., Simpson, J. P., Kane, A. D., Menon, D. K., Rueckert, D., & Glocker, B. (2017) · Medical Image Analysis · doi:10.1016/j.media.2016.10.004 · Cited by 3,498
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Self-citationArtificial intelligence in cancer imaging: Clinical challenges and applications
Bi, W. L., Hosny, A., Schabath, M. B., Giger, M. L., Birkbak, N. J., Mehrtash, A., Allison, T., Arnaout, O., Abbosh, C., Dunn, I. F., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21552 · Cited by 1,846
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432
Self-citation
Metadata
- Authors
- Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., Tsien, C., Mikkelsen, T., Wong, E. T., Chamberlain, M. C., Stupp, R., Lamborn, K. R., Vogelbaum, M. A., van den Bent, M. J., & Chang, S. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-04-10
- Volume
- 28
- Issue
- 11
- Pages
- 1963-1972
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2162643152
- Cited by
- 3,836
- References
- 6
- FWCI
- 69.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. https://app.cochat.ai/papers/10.1200/jco.2009.26.3541
- The paper
- Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., Tsien, C., Mikkelsen, T., Wong, E. T., Chamberlain, M. C., Stupp, R., Lamborn, K. R., Vogelbaum, M. A., van den Bent, M. J., & Chang, S. M. (2010). Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.26.3541
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
